Skip to main content
Gastroenterology and Hepatology From Bed to Bench logoLink to Gastroenterology and Hepatology From Bed to Bench
. 2019 Spring;12(2):131–137.

ANXA2, PRKCE, and OXT are critical differentially genes in Nonalcoholic fatty liver disease

Mostafa Rezaei Tavirani 1, Majid Rezaei Tavirani 2, Mona Zamanian Azodi 1
PMCID: PMC6536018  PMID: 31191837

Abstract

Aim:

Identification of prominent genes which are involved in onset and progress of steatosis stage of Nonalcoholic fatty liver disease (NAFLD) is the aim of this study.

Background:

NAFLD is characterized by accumulation of lipids in hepatocytes. The patients with steatosis (the first stage of NAFLD) will come across nonalcoholic steatohepatitis (NASH) and finally hepatic cirrhosis. There is correlation between cirrhosis and hepatic cancer. However, ultrasonography is used to diagnose NAFLD, biopsy is the precise diagnostic method.

Methods:

Gene expression profiles of 14 steatosis patients and 14 controls are retrieved from gene expression omnibus (GEO) and after statistical validation top 250 differentially expressed genes (DEGs) were determined. The characterized DEGs were included in network analysis and the central DEGs were identified. Gene ontology (GO) performed by ClueGO analysis of DEGs to determine critical biological terms. Role of prominent DEGs in steatosis is discussed in details.

Results:

Numbers of 31 significant DEGs including 20 up-regulated and 11 down-regulated ones were determined. Nine biological groups including 27 terms were recognized. Negative regulation of low-density lipoprotein particle receptor catabolic process, TRAM-dependent toll-like receptor signaling pathway, and regulation of hindgut contraction which were related to ANXA2, PRKCE, and OXT respectively were determined as critical biological term groups and DEGS.

Conclusion:

Deregulation of ANXA2, PRKCE, and OXT is a critical event in steatosis. It seems these three genes are suitable biomarker to diagnosis of steatosis.

Key Words: Nonalcoholic fatty liver disease, Biomarker, Gene

Introduction

Accumulation of lipids in hepatocytes occurs in NAFLD which is seen in association with various diseases, toxins, and drugs. There is evidence that level hepatic enzymes change significantly. Steatosis is the first stage of NAFLD which can convert to nonalcoholic steatohepatitis (NASH) and finally cirrhosis (1, 2). There is correlation between cirrhosis and liver cancer (3). Usually, ultrasonography check of liver is diagnostic method for NAFLD. However, precious diagnosis requires liver biopsy (4). Several attempts are done to find noninvasive biomarkers for NAFLD. Proteomics, genomics, metabolomics, and bioinformatics are used to analyze molecular aspect of NAFLD (5-8). In one study cytokeratin-18 fragment level is introduced as noninvasive biomarker for NAFLD while in the other investigation a large number of biomarkers are tabulated and introduced to diagnose NAFLD (9, 10).

PPI network analysis is used to interact large numbers of proteins (or genes) in a network to provide possible screening tool. In this approach few genes among interacted genes play critical role to construct the network, and therefore have many connection with the other elements of the network. These types of genes are known as hubs. The other types of important elements of network are known as bottlenecks. The common hubs and bottlenecks are famous as hub-bottlenecks (11, 12). Gene ontology is useful method to identify biological terms related to investigate genes. In this regard, molecular function, biological processes, cellular component, and biochemical pathways as molecular features related to the query genes recognize (13). In this study, gene expression profiles of NAFLD (steatosis stage) patients are compared with control (data are retrieved from GEO) and the significant DEGs are included into interactome to find critical genes which are involved in NAFLD. Gene ontology is used to identify biological terms related to NAFLD. The finding can be considered to determine possible diagnostic and therapeutic biomarkers.

Methods

Gene expression profiles of 14 non-alcoholic fatty liver disease (NAFLD) stage steatosis patients and 14 controls, series GSE48452, GPL11532 were obtained from GEO. Demography of samples are tabulated in the table 1 (14). Liver biopsy samples were analyzed by array-based DNA methylation and mRNA expression. Profiles were compared via boxplot analysis and top 250 significant DEGs were considered for more analysis. The characterized DEGs with fold change more than 1.5 were determined and included in PPI network. The query DEGs and 100 added relevant genes were included in network to constructed PPI network by using STRING database and Cytoscape software (15, 16). The network was analyzed via Network analyzer plugin of Cytoscpe software. Biological terms relative to the query DEGs were determined and clustered by ClueGO (17). Critical DEGs based on network analysis and GO enrichment were determined. For more understanding a PPI network including the critical DEGs and their direct neighbors was built.

Table 1.

Demography of controls and patients    (14) 

R Accession Group Sex Age Bmi
1 GSM1178970 Control male 53 25.8
2 GSM1178971 Control female 51 23.6
3 GSM1178972 Control male 77* 26.9*
4 GSM1178973 Control male 23 26.6
5 GSM1178974 Control male 80 25.8
6 GSM1178977 Control male 68 26.4
7 GSM1178978 Control female 45 20.1
8 GSM1178979 Control female 44 29.4
9 GSM1178986 Steatosis female 46 43.5
10 GSM1178988 Steatosis female 24 51.9
11 GSM1178989 Steatosis female 32 48.6
12 GSM1178993 Steatosis female 38* 42.4*
13 GSM1178998 Control female 28 17.4
14 GSM1178999 Steatosis female 47 56
15 GSM1179009 Control female 38* 30.0*
16 GSM1179010 Control female 42 23.3
17 GSM1179011 Steatosis male 61 40.3*
18 GSM1179018 Control female 73 21
19 GSM1179021 Steatosis male 38* 55.5*
20 GSM1179023 Steatosis female 33 40.9
21 GSM1179024 Control female 44 24.9
22 GSM1179025 Steatosis female 39* 53.6*
23 GSM1179027 Steatosis male 47* 47.9*
24 GSM1179029 Steatosis male 65 43.7
25 GSM1179031 Control female 60* 30.8*
26 GSM1179034 Steatosis female 42 49.6
27 GSM1179037 Steatosis female 32 60.2
28 GSM1179040 Steatosis female 39* 41.8*

Results

Gene expression profiles of 14 steatosis samples and 14 controls are analyzed via boxplot analysis. As it is shown in the figure 1 data obey from median centered distribution, therefore they are statistically comparable.

Figure 1.

Figure 1

Boxplot presentation of gene expression profiles of 14 steatosis patients and 14 controls

Among 250 top significant DEGs, 31 individuals were characterized and included in network construction. In figure 2, the 31 DEGs and their LogFC are shown. In this figure, it is appeared that there are 20 up – regulated and 11 down – regulated DEGs. The network was built by 31 query DEGs and 100 added relevant ones. As it is illustrated in figure 3, 4 DEGs were not recognized and the network was constructed by 127 nodes and 1576 edges.

Figure 2.

Figure 2

LogFC 31 DEGs including 20 up-regulated and 11 down-regulated ones is illustrated

Figure 3.

Figure 3

The main connected component including 120 nodes and 1576 edges is shown. The nodes are layout based on degree value. PRKCE, OXT, and ANXA2, the query DEGs are shown in the left side of figure

Figure 4.

Figure 4

Nine groups including 27 terms relevant to the 31 DEGs are shown

Numbers of 7 nodes were isolated and the main connected component contains 120 nodes. Biological terms relative to the 31 DEGs are presented in the figure 4. The 27 terms are grouped in 9 classes. Details of figure 4 and additional information are tabulated in table 2. As it is shown in this table only 9 genes among 31 DEGs are involved in the biological terms. As it is shown in the figure 3 and table 2 three important DEGs are included PRKCE, OXT, and ANXA2. These three DEGs and their direct neighbors are shown in figure 5.

Table 2.

Numbers of 27 terms relevant to the 31 DEGs are clustered in the 9 groups. %G/T refers to percentage of genes that are involved in term. Gene column shows the gene which participates in the related term

R GO Term Ontology Source Group % G/T Gene
1 pyruvate secondary active transmembrane transporter activity GO_MolecularFunction-EBI-QuickGO-GOA_20.11.2017_00h00 1 100 SLC16A7
2 CSAD decarboxylates 3-sulfinoalanine to hypotaurine REACTOME_Reactions_20.11.2017 2 100 CSAD
3 HSD17B11 dehydrogenates EST17b to E1 3 100 HSD17B11
4 STARD5 binds DCA, LCA 4 100 STARD5
5 Golgi to plasma membrane CFTR protein transport GO_BiologicalProcess-EBI-QuickGO-GOA_20.11.2017_00h00 5 50 KRT18
6 Defective ABCC6 causes pseudoxanthoma elasticum (PXE) REACTOME_Pathways_20.11.2017 6 100 ABCC6
7 Defective ABCC6 does not transport organic anion from cytosol to extracellular region REACTOME_Reactions_20.11.2017
8 Oxytocin receptor bind oxytocin 7 50 OXT
9 regulation of hindgut contraction GO_BiologicalProcess-EBI-QuickGO-GOA_20.11.2017_00h00
10 positive regulation of hindgut contraction 100
11 DAG stimulates protein kinase C-delta 8 50 PRKCE
12 TRAM-dependent toll-like receptor signaling pathway
13 TRAM-dependent toll-like receptor 4 signaling pathway
14 positive regulation of cellular glucuronidation 100
15 Expression of annexin A2 REACTOME_Reactions_20.11.2017 9 50 ANXA2
16 negative regulation of development of symbiont involved in interaction with host GO_BiologicalProcess-EBI-QuickGO-GOA_20.11.2017_00h00 100
17 positive regulation of low-density lipoprotein particle clearance
18 catabolism by organism of protein in other organism involved in symbiotic interaction
19 catabolism by host of substance in symbiont
20 metabolism by host of symbiont macromolecule
21 metabolism by host of symbiont protein
22 negative regulation of low-density lipoprotein particle receptor catabolic process 50
23 catabolism by host of symbiont macromolecule 100
24 positive regulation of low-density lipoprotein particle receptor binding
25 positive regulation of low-density lipoprotein receptor activity
27 catabolism by host of symbiont protein
27 positive regulation of receptor-mediated endocytosis involved in cholesterol transport 50

Figure 5.

Figure 5

Network including PRKCE, OXT, and ANXA2 and their direct neighbors is illustrated. The nodes are layout based on degree value. Bigger size is corresponded to high value of degree. Color from blue to red refers to increment of degree value

Considering important role of oxytocin in our study and well-known function of this hormone in females, expression change of OXT in male patients and control was investigated. Therefore, possible bias of sex effect is considered. It was appeared that fold change of oxytocin was equal to 3.76 (LogFC = 1.91) and this hormone was the top deregulated DEGs. Demography of samples and boxplot analysis are shown in table 3 and figure 6.

Table 3.

Demography of 4 male patients and 4 male controls which their gene expression profiles are compared is shown

R Accession Group Sex Age Bmi
1 GSM1178970 Control male 53 25.8
3 GSM1178972 Control male 77* 26.9*
4 GSM1178973 Control male 23 26.6
6 GSM1178977 Control male 68 26.4
17 GSM1179011 Steatosis male 61 40.3*
19 GSM1179021 Steatosis male 38* 55.5*
23 GSM1179027 Steatosis male 47* 47.9*
24 GSM1179029 Steatosis male 65 43.7

Figure 6.

Figure 6

Boxplot analysis of gene expression profiles of 4 control in comparison with 4 steatosis patients samples

Discussion

Gene profile analysis can provide useful information about molecular mechanism of diseases (18, 19). In this study network analysis is used to screen significant DEGs which differentiated steatosis stage of NAFLD patients from controls. As it is shown in the figure 1, statistically samples are comparable because distribution of data is median centric. Therefore, more investigations about samples are possible. As it is shown in figure 2, up-regulation is prominent relative to down-regulation in NAFLD. Numbers of 20 DEGs are up-regulated while 11 down-regulated genes are represented. However, PRDM10, PIK3CA, GAPDH, ALB, SRC, and TP53 are the hubs of the network but PRKCE, OXT, and ANXA2 the query DEGs play significant roles in the PPI network. PRKCE and OXT are upregulated genes while ANXA2 is down regulated one (see figure 2). In figure 3, positions of these three DEGs relative to the other query DEGs are layout and illustrated. The other query DEGs are characterized with weak centrality role in the network. Among 31 DEGs, seven ones containing BEAN1, CCDC82, GOLGA8O, GOLGA8T, HAPLN4, RAPGEFL1, and STARD5 were not included in the network and remained as isolated nodes. GO analysis indicates that 9 DEGs are involved in the 27 biological terms which are clustered in the 9 groups (see figure 4 and table 2). Group 9: negative regulation of low-density lipoprotein particle receptor catabolic process is the largest group including 13 biological terms. The second and third larger groups (groups 8 and 7) are TRAM-dependent toll-like receptors signaling pathway (including 4 terms) and regulation of hindgut contraction (containing 3 terms), respectively. ANXA2, PRKCE, and OXT are complicated in the groups 9, 8, and 7, respectively. These three DEGs are involved in 20 terms (74% of all biological Terms). As it is shown in the figure 5, 77 nodes (64% of PPI network nodes) are directly linked to PRKCE, OXT, and ANXA2. It seems ANXA2, PRKCE, and OXT are central DEGs among 31 query DEGs which their deregulation is functionally significant event in NAFLD.

Since oxytocin is a well-known female hormone and there are no sufficient documents about its role in men, we design another analysis that was resulted from comparison between male patients and control (see table 3 and figure 6). In this analysis OXT appeared as the top DEGs based on fold change. Therefore, presence of oxytocin among three important DEGs in NAFLD is depended to both male and female patients.

Four biological terms in group 9 are about regulation of low-density lipoprotein (LDL). LDL is a cholesterol-carrying agent in human plasma which LDL receptor regulates its plasma level. Investigation showed that raising cholesterol content of liver hepatocytes leads to fall of LDL receptors in liver which causes increment of LDL level of plasma. This process is seen after digestion of diets rich in saturated fat and cholesterol (20). It seems that deregulation of ANXA2 effects on storage of fat in lever via deregulation of clearance of plasma cholesterol. Sun et al. reported that there is correlation between low-density lipoprotein cholesterol and NAFLD prevalence (21). However, role of ANXA2 in NAFLD is reported previously, here it is introduced as the top related gene in NAFLD (especially steatosis stage).

Positive regulation of cellular glucuronidation is one of group 8 biological process. Glucuronidation is a major biochemical pathway that plays role in cellular detoxification. In this pathway, the highly hydrophilic glucuronide group transfers to hydrophobic substrates which are less toxic and can be exerted easily relative to the initial substances (22). Role of this protective process was studied in drug metabolism of NAFLD patients (23). It can be concluded that up-regulation of PRKCE which promotes positive regulation of cellular glucuronidation is a protecting activity in NAFLD.

Regulation of hindgut contraction is a term which is related to oxytocin. It is reported that positive regulation of hindgut (the posterior part of the alimentary canal, including the rectum, and the large intestine) is appositive regulation of smooth muscle which positively regulates hindgut contraction. This terms is responsible for positive regulation of digestion (https://www.ebi.ac.uk/QuickGO/term/GO:0060450). In conclusion up-regulation of OXT stimulates digestion in steatosis stage of NAFLD.

Precious analysis revealed that ANXA2, PRKCE, and OXT are three important genes that are involved in steatosis stage of NAFLD. Significant expression change, participation in prominent biochemical pathways, and large number of connections with the other genes imply that these DEGs be considered as critical genes relative to NAFLD. It can be suggested that suitable quantity profiles of ANXA2, PRKCE, and OXT be validated to manage steatosis stage of NAFLD.

Acknowledgment

This research is supported by Shahid Beheshti University of Medical Sciences.

Conflict of interests

The authors declare that they have no conflict of interest.

References

  • 1.Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes. Hepatol. 2006;44:865–73. doi: 10.1002/hep.21327. [DOI] [PubMed] [Google Scholar]
  • 2.Gaggini M, Morelli M, Buzzigoli E, DeFronzo R, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nut. 2013;5:1544–60. doi: 10.3390/nu5051544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res. 2006;35:204–14. doi: 10.1016/j.hepres.2006.04.007. [DOI] [PubMed] [Google Scholar]
  • 4.Altinbas A, Sowa JP, Hasenberg T, Canbay A. The diagnosis and treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2015;61:159–69. [PubMed] [Google Scholar]
  • 5.Naik A, Košir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics. 2013;102:84–95. doi: 10.1016/j.ygeno.2013.03.007. [DOI] [PubMed] [Google Scholar]
  • 6.Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatol. 2005;42:665–74. doi: 10.1002/hep.20838. [DOI] [PubMed] [Google Scholar]
  • 7.Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism. 2011;60:404–13. doi: 10.1016/j.metabol.2010.03.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yu C, Xu C, Xu L, Yu J, Miao M, Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol. 2012;56:241–7. doi: 10.1016/j.jhep.2011.05.027. [DOI] [PubMed] [Google Scholar]
  • 9.Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res. 2013;1:7. doi: 10.1186/2050-7771-1-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin‐18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatol. 2009;50:1072–8. doi: 10.1002/hep.23050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Safaei A, Tavirani MR, Oskouei AA, Azodi MZ, Mohebbi SR, Nikzamir AR. Protein-protein interaction network analysis of cirrhosis liver disease. Gastroenterol Hepatol Bed Bench. 2016;9:114. [PMC free article] [PubMed] [Google Scholar]
  • 12.Safari-Alighiarloo N, Taghizadeh M, Rezaei-Tavirani M, Goliaei B, Peyvandi AA. Protein-protein interaction networks (PPI) and complex diseases. Gastroenterol Hepatol Bed Bench. 2014;7:17. [PMC free article] [PubMed] [Google Scholar]
  • 13.Rezaei-Tavirani M, Mansouri V, Mahdavi SM, Valizadeh R, Rostami-Nejad M, Zali MR. Introducing crucial protein panel of gastric adenocarcinoma disease. Gastroenterol Hepatol Bed Bench. 2017;10:21–8. [PMC free article] [PubMed] [Google Scholar]
  • 14.Ahrens M, Ammerpohl O, Von Schönfels W, Kolarova J, Bens S, Itzel T, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab. 2013;18:296–302. doi: 10.1016/j.cmet.2013.07.004. [DOI] [PubMed] [Google Scholar]
  • 15.Zhi J, Sun J, Wang Z, Ding W. Support vector machine classifier for prediction of the metastasis of colorectal cancer. Int J Mol Med. 2018;41:1419–26. doi: 10.3892/ijmm.2018.3359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45:D362–8. doi: 10.1093/nar/gkw937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Tian R, Li X, Gao Ye, Li Y, Yang P, Wang K. Identification and validation of the role of matrix metalloproteinase-1 in cervical cancer. Int J Oncol. 2018;52:1198–208. doi: 10.3892/ijo.2018.4267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JR, Elkahloun AG. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res. 1999;59:5656–61. [PubMed] [Google Scholar]
  • 19.Loring J, Wen X, Lee J, Seilhamer J, Somogyi R. A gene expression profile of Alzheimer's disease. DNA Cell Biol. 2001;20:683–95. doi: 10.1089/10445490152717541. [DOI] [PubMed] [Google Scholar]
  • 20.Goldstein JL, Brown MS. Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circul. 1987;76:504–7. doi: 10.1161/01.cir.76.3.504. [DOI] [PubMed] [Google Scholar]
  • 21.Sun DQ, Liu WY, Wu SJ, Zhu GQ, Braddock M, Zhang DC, et al. Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. Oncotarget. 2016;7:5728. doi: 10.18632/oncotarget.6799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Perreault M, Białek A, Trottier J, Verreault M, Caron P, Milkiewicz P, et al. Role of glucuronidation for hepatic detoxification and urinary elimination of toxic bile acids during biliary obstruction. Plos One. 2013;8:e80994. doi: 10.1371/journal.pone.0080994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Naik A, Belič A, Zanger UM, Rozman D. Molecular interactions between NAFLD and xenobiotic metabolism. Front Genet. 2013;4:2. doi: 10.3389/fgene.2013.00002. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gastroenterology and Hepatology From Bed to Bench are provided here courtesy of Shahid Beheshti University of Medical Sciences

RESOURCES